Adagio Therapeutics Inc - ESG Rating & Company Profile powered by AI
The Disclosure rating includes 17 UN SDGs including: 'Affordable & Clean Energy', 'Decent Work & Economic Growth' and 'Partnerships for the Goals'. Browse to the bottom of this webpage for potential risks for Adagio Therapeutics Inc based on industry, location and size. Other companies in the scoring peer group for Adagio Therapeutics Inc are shown below.
Adagio Therapeutics Inc in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Adagio Therapeutics Inc | 8.0 | High |
| 1 | Analytik Jena AG | 8.0 | High |
| 1 | Amniotics AB (publ) | 8.0 | High |
| ... | ... | ... | |
| 182 | Wesana Health Holdings Inc | 0.0 | Low |
| 182 | rEVO Biologics Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Adagio Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Adagio Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Adagio Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Adagio Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Adagio Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Adagio Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Adagio Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Adagio Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Adagio Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Adagio Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Adagio Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Adagio Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Adagio Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Adagio Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Adagio Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Adagio Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Adagio Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Adagio Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.